Glioblastoma multiforme is considered to be one of the most aggressive types of tumors of the central nervous system, with a poor prognosis and short survival periods of ~ one year. The current protocol for glioblastoma treatment includes the surgical excision of the primary tumor followed by radio and chemotherapy. Photodynamic therapy (PDT) is considered a promising strategy for the treatment of several types of tumors. Phthalocyanines (Pcs) are good photosensitizers (PSs) for PDT because they induce cell death in several cellular models. ZnPc (Zn(II)phthalocyanine) is a well-known Pc, extensively tested in different cells and tumor models, but its evaluation on a glioblastoma model has been poorly studied. Herein, we compare the capacity of ZnPc and one of its derivatives, Zn(II)tetraminephthalocyanine (TAZnPc), to photoinactivate glioblastoma cells (T98G, MO59, LN229 and U87-MG) in culture. We measured the cellular uptake, the toxicity in the dark and the subcellular localization of the different Pcs, as well as the clonogenic capacity of surviving cells after PDT. The mechanism of cell death induced after PDT was determined by measuring caspase 3 activation, DNA fragmentation, phosphatidylserine externalization, mitochondrial morphological changes and loss of mitochondrial membrane potential as well as lysosomal membrane integrity. Overall, ZnPc and TAZnPc present good properties to be used as PSs with photoinactivation capacity on glioblastoma cells.
Gliomas account for approximately 70% of the new cases of primary brain tumors diagnosed in adults in the United States each year1. Glioblastomas multiforme (classified by the World Health Organization as type IV glioma) are one of the most common and aggressive forms of tumors of the central nervous system and, in the United States, more than 10,000 new cases are reported every year2. The location of these tumors in critical areas of the brain makes them difficult to be removed by surgery whereas the blood-brain barrier limits the access of drugs to reach their site of action thus complicating even more the possibility of controlling their growth3,4.
At present, the protocol for treatment of Glioblastomas multiforme involves surgical resection followed by chemo and radiotherapy that results in an average survival time of approximately 14.6 months5. Due to the highly invasive nature of these tumors, the surgical elimination of the primary tumor bulk is usually not curative and the presence of invasive infiltrating cells leads to the development of secondary tumors either close or distant to the location of the primary one. In addition, as with other tumors, cancer stem cells (CSCs) play a role in the growth, maintenance and metastasis of these tumors, as well as in the resistance to radio and chemotherapy and tumor recurrence after treatment6,7,8.
Photodynamic therapy (PDT) is an effective strategy for the treatment of several cancers, microbial diseases, diagnosis, as well as for cosmetic purposes9. PDT involves a non-toxic compound known as photosensitizer and visible light of the wavelength absorbed by the PS which in the presence of oxygen leads to the generation of singlet oxygen (1O2) and/or reactive oxygen species (ROS) that can damage cellular constituents leading to cell death10,11 followed by tumor regression12,13,14,15. As these reactions occur only in the local area of the light-absorbing photosensitizer, the biological responses are limited to the area that has been irradiated. Ideal PS should be accumulated in target tissues and rapidly eliminated to prevent secondary effects related to photosensitivity16.
The main purpose of using PDT to treat tumors is to trigger the destruction of tumor cells by induction of cell death. Several factors influence the type of cell death that occurs after PDT: the properties, concentration, and subcellular localization of the PS, the oxygen available at the site of irradiation, the dose of light delivered and the cell type17. After PDT, cells can undergo at least two types of cell death, that is, apoptosis or necrosis. The first refers to the physiological cell death that occurs without triggering inflammation or immunological responses whereas necrosis is a fast, non-regulated and aggressive form of cell death, commonly associated with inflammatory processes18.
Since PDT effects are limited to the site of irradiation, the use of this therapeutic approach for the treatment of high infiltrating gliomas has become a topic of interest for many researchers. Several studies have been performed showing the potentiality of the therapy using different PSs19,20,21,22,23,24. Phthalocyanines (Pcs) and their derivatives have been considered excellent PSs (second generation) for PDT in numerous types of tumors. This type of molecule strongly absorbs in the red and near infrared regions of the visible spectrum, which corresponds to the tissue optical window12,25,26. In addition, Pcs present high photo and chemical stability27,28. Zn(II)phthalocyanine (ZnPc) is a well-known Pc and several reports have proved its properties as PS for PDT13,28,29. However, to the best of our knowledge, only a few reports analyzed the effectiveness of Pcs on a glioblastoma cell model30.
The aim of the present study was to evaluate the efficacy of two phthalocyanines: ZnPc and Zn(II)tetraminephthalocyanine (TAZnPc) to photo-inactivate glioblastoma cells in vitro. Dark toxicity, cellular uptake and subcellular localization of ZnPc and TAZnPc were determined. In addition, effectiveness of these Pcs to reduce cell viability in culture as well as the clonogenic capacity of post-PDT surviving cells were examined. Finally, the type of cell death triggered after PDT was assessed evaluating the disruption of mitochondrial integrity, loss of mitochondrial membrane potential (MMP), activation of caspase 3, loss of lysosomal membrane potential and DNA fragmentation.
The Pcs (Fig. 1) used in this work were synthetized as described under Materials and Methods. The absorption spectra of TAZnPc in DMF presents a higher red-shifted λmax (702 nm) compared to ZnPc (670 nm)31 (Supplemental Figs 1 and 2). Fluorescence quantum yields (ФF) of TAZnPc was calculated ФF(TAZnPc) = 0.03, by comparative method using ZnPc as standard (ФF(ZnPc) = 0.17)32. The singlet oxygen production in DMF was determined by TAZnPc, ΦΔ = 0.45 ± 0.02 (Supplemental Fig. 3), this value is similar to that of non-modified ZnPc (0.56)33.
Dark cytotoxicity of photosensitizers
To evaluate if the Pcs used in this study affect cell viability in the absence of irradiation, we examined the effect of the addition of Pcs to glioma cell cultures. Cells were incubated during 18 hours with different concentrations of the Pc (in the range of 0–20 µM) diluted in Dulbecco’s modified Eagle medium (DMEM) supplemented with 4% FBS and cell viability measured. Results in Fig. 2a show that, for all Pcs evaluated in T98G cells, concentrations of 0.5 µM was not cytotoxic in the absence of irradiation, with a survival fraction higher than 90% as compared to control cells cultured in the absence of Pc. However, higher concentrations of photosensitizer lead to a reduction in cell viability, showing survival fractions lower than 90%. Based on these results, hereafter, all the following experiments were performed using Pc concentrations ≤ 0.5 µM. Results obtained in T98G cells are similar to those observed in three additional glioma cell lines (Supplementary Fig. 5).
To evaluate the cellular uptake of the different Pcs, T98G cells were incubated during different times in the presence of each Pc (0.5 μM) and the relative amount of each Pc incorporated into the cells was evaluated both by the direct measurement of fluorescence and also by flow cytometry. As can be observed in Fig. 2b, the results obtained by both methodologies indicate that ZnPc and TAZnPc uptake increased over time.
The subcellular accumulation and localization of the sensitizers is critical to evaluate the potentiality for PDT, since the singlet oxygen generated after illumination presents a short lifetime and a migration distance of approximately 1 μm34. Consequently, the subcellular localization of TAZnPc and ZnPc was examined by confocal microscopy using organelle-specific probes. As can be observed in Fig. 3, TAZnPc and ZnPc are accumulated both in cytoplasm and in the perinuclear region. No Pcs was detected in the nucleus. When we analyzed the possible co-localization of the PS signal with the organelle-specific probes we observed that TAZnPc accumulates preferentially in lysosomes (Pearson’s coefficient 0.7539 ± 0.012), whereas ZnPc accumulates preferentially in mitochondria (Pearson’s coefficient 0.7336 ± 0.017) but also partially in lysosomes (Pearson’s coefficient 0.4953 ± 0.011) (Fig. 3a,c). Moreover, we analyzed the fluorescence spectra in order to assess the identity of the fluorescence. As can be seen in the fluorescence spectra presented in the middle panel, when cells were excited with a laser at 635 nm, cells incubated with ZnPc present an intracellular signal with a maximum at 675 nm whereas the cells incubated with TAZnPc show a maximum at 711 nm, confirming the Pc specific fluorescence (Fig. 3b).
The photocytotoxicity of the different Pcs in T98G cells was assessed at three different Pc concentrations 0.125, 0.25 and 0.5 µM. After 18 hours of incubation with one of the Pcs, cells were irradiated using two light doses: 10 or 27 J/cm2 and viability measured 24 hours after irradiation. Results show a clear cytotoxic effect on cells subjected to the combination of light and either TAZnPc or ZnPc (Fig. 4a,b, respectively). Both Pcs were innocuous in the absence of light (0 J/cm2) at the Pc concentrations tested, with survival fraction higher that 90%. In addition, neither light doses don’t reduce cell viability in absence of Pc indicating that there was no detectable thermal effect during the irradiation of the cells. As can be observed, a ~90% reduction in cell survival is achieved using either ZnPc or TAZnPc at 0.5 µM combined with a light dose of 27 J/cm2, meanwhile, when a lower light dose was used (10 J/cm2) ZnPc-PDT was able to reduce the cell viability by ~80% whereas TAZnPc was less effective to photoinactivate T98G cells using a lower light dose (10 J/cm2) showing a reduction of ~46% in cell viability. These results shown a clear relation between the Pc concentration and the light dose delivered in the photo inactivation capacity.
Since the recurrence of tumors after treatment is based on the capacity of surviving cells to proliferate, we evaluated the clonogenic capacity of T98G cells after PDT. For this, cells were treated with Pcs at 0.5 µM, irradiated using two light doses (10 and 27 J/cm2), and 24 hours after PDT, cells were washed, counted and plated. 8–10 days later, colony formation was assessed and the survival fraction determined for each treatment. As can be seen in Fig. 5, no colonies were observed in cells treated with ZnPc combined with both light doses. However, as was observed with the alamarBlue assay, the combination of TAZnPc with 10 J/cm2 reduces cell viability in ~45%, whereas the application of a higher light dose completely abolishes the colony formation capacity of T98G cells.
Mode of cell death triggered by PDT
Since it has been previously reported that PDT treatment of tumor cells either in vitro or in vivo can induce cell death by different mechanisms18, we evaluated the pathway of cell death triggered upon treatment of cells with the combination of Pc plus light.
To determine if apoptosis was induced in T98G cells using the different Pcs for PDT, treated cells were fixed at different times post irradiation (1, 3 or 24 hours) and stained using anti cleaved caspase 3 (CC3) antibody and 4′,6-diamidino-2-phenylindole (DAPI). Fragmented nuclei positive for CC3 were considered as apoptotic cells. As can be seen in Fig. 6a, PDT using either ZnPc or TAZnPc induces programmed cell death in glioblastoma cell cultures. The highest percentage of adherent cells undergoing apoptosis was observed 3 hours after irradiation with 10 J/cm2 in cells treated with ZnPc (~65%). However, samples measured 24 hours post PDT using the same light dose showed less CC3+ fragmented nuclei cells since those that had previously undergone apoptosis become detached and were not being detected at this time point by the assay. Small amounts (<5%) of attached CC3+ cells with fragmented nuclei were observed in samples treated with ZnPc and 27 J/cm2. Cells treated with TAZnPc showed the highest amount of CC3+ fragmented nuclei 3 hours after irradiation with 27 J/cm2 (~31%).
Since only attached cells were taken into account in the above-mentioned analysis, we additionally measured early signals (three hours after PDT) of apoptosis by detection of phosphatidylserine externalization (Annexin V) and propidium iodide (PI) staining followed by flow cytometry analysis. As shown in Fig. 7, phosphatidylserine externalization was observed after irradiation with 10 or 27 J/cm2 in cells treated with ZnPc. Upon the application of a light dose of 10 J/cm2, 72.6 ± 5.8% of cells classified as early apoptotic cells, whereas 12.83 ± 2.48% of de total cell population showed signs of late apoptosis. On the other hand, when a higher light dose was used, we observed 68.2 ± 4.6 and 24.3 ± 0.6% of early and late apoptotic cells respectively. However, in the case of TAZnPc, a significant population of Annexin V positive cells was observed only after irradiation with 27 J/cm2. This population was composed by 51.2 ± 4.9 and 15.1 ± 2.4% of early and late apoptosis cells respectively. These results are in line with the above-mentioned observations regarding the activation of caspase 3 and nuclei fragmentation indicating that higher light doses are required to induce apoptosis upon TAZnPc treatment than with ZnPc. A non-significant cell population underdoing necrosis was observed in both treatments with both Pcs, suggesting that the apoptotic pathway is the preferential cell death mechanism triggered after irradiation of the cells.
Mitochondrial disruption after PDT
It has been previously proposed that the cell damage triggered by PDT begins at the subcellular compartment in which the Pc is accumulated35. Since previous reports suggest that ZnPc could be localized in mitochondria36, Golgi37, lysosomes and endoplasmic reticulum38, and considering that we observed that there is colocalization of ZnPc with a mitochondria-specific probe (Fig. 3a) we evaluated the effect of PDT on mitochondria, a key organelle involved in apoptosis. As can be observed in Fig. 8a,b, an increase in the number of cells positive for Annexin V (early apoptosis signal) is accompanied by a decrease in the number of cells positive for the mitochondrial probe MitoTracker red CMXRos in cells treated either with ZnPc or TAZnPc. Interestingly, this observation is already evident at a low light dose for ZnPc-treated cells but only at the higher doses for cells treated with TAZnPc in accordance with the results shown in Fig. 7. Histograms of fluorescence intensity for MitoTracker Red in cells treated with either of the Pcs mentioned above show a loss of signal, indicating a decrease in mitochondrial membrane potential (MMP) after PDT (Fig. 8c,d). Moreover, we assessed mitochondrial morphology by confocal microscopy and, as shown in Fig. 8e, a clear morphological change was observed in cells treated with either ZnPc or TAZnPc. Additionally, a light dose dependence on injury was observed supporting our previous results. Taken together, these results show that mitochondria are clearly affected by PDT using ZnPc and TAZnPc.
Lysosomal disruption after PDT
Lysosomes are critical organelles for the cell. These subcellular compartments plays critical roles in controlling cell homeostasis as well as in triggering cell death39. Since we observed lysosomal accumulation of both Pcs, we analyzed the effect of the irradiation on these organelles. For this, we used the Lysotracker green retention as an indicator of lysosome membrane integrity and membrane potential changes. Since we observed that there is a rapid induction of apoptosis after irradiation in cells incubated with ZnPc or TAZnPc, we measured the early (1 hour after PDT) loss of Lysotracker green fluorescence. Results shown in Fig. 9 indicate that after irradiation with 27 J/cm2 on cells incubated with ZnPc or TAZnPc, there is a significant reduction in the Lysotracker green signal, suggesting that lysosomes were disrupted after irradiation. In concordance with previous results, no significant loss of LysoTracker probe retention is observed in cells subjected to PDT with TAZnPc at the lower light dose or in cells irradiated without Pcs. This result suggests that this organelle is disrupted after PDT.
DNA fragmentation after PDT
To evaluate the end-point hallmark of apoptosis, that is DNA laddering, cells treated with the different Pcs were used to isolate DNA and DNA laddering was determined. Results shown in Supplementary Fig. 7 showed no evident signals of DNA fragmentation in either of the two light doses used, in the absence of Pc (control). By contrast, cells treated with TAZnPc show a typical DNA fragmentation pattern 24 hours after irradiation with 27 J/cm2. In the case of cells treated with ZnPc, DNA fragmentation was also evident at 24 hours showing mainly fragments of low molecular length. However, when DNA was isolated at an early time point (6 hours after PDT with ZnPc) the laddering pattern was more evident. The pattern of DNA oligonucleotide fragmentation observed suggests differences in the apoptosis timing after irradiation of cells treated with ZnPc or with TAZnPc, being the induction of apoptosis faster in the first case (Supplementary Fig. 7).
Photocytotoxicity in other glioma cells
The photocytotoxicity of the different Pcs was evaluated in three additional glioma cell lines (MO59, LN229 and U87-MG). Both Pcs were evaluated at three different concentrations 0.125, 0.25 and 0.5 µM following the PDT protocol described above for T98G cells. Pcs dark toxicity was assessed in the three cell lines with results similar to the reported above for T98G cells (Supplementary Data). We observed that, similar to the results for T98G cells, both TAZnPc and ZnPc are able to trigger a reduction in cell viability when the cells are irradiated. (Fig. 10a,b, respectively). In the three cell lines analyzed, either light or Pcs alone were not able to reduce cell viability (survival fraction higher that 90%) whereas ZnPc at 0.5 µM combined with a light dose of 27 J/cm2 reduced ~90% of cell viability in all cell lines evaluated. In the case of TAZnPc, only ~70% of reduction was observed in the three cell lines when the highest Pc concentration and light dose were delivered. When the lower light dose was used (10 J/cm2), ZnPc at 0.5 µM gave similar results in all cell lines achieving a reduction of ~80% in cell viability. By contrast, TAZnPc was less effective to photoinactivate the cells with ~20% of reduction in cell viability in the cell lines examined. A non-significant reduction in cell viability was observed in all the cell lines using TAZnPc at 0.125 µM whereas ZnPc still was capable of reducing the cell viability in all glioma cell lines when used at the same concentration. A clear correlation between the Pc concentration and the light dose delivered was observed in the three cell lines in the photoinactivation capacity.
The development of new PSs is a mayor goal in the current research on PDT and much more so for tumors in which other therapies have resulted ineffective as is the case of brain tumors. One of the determinants for brain tumor recurrence is probably the growth pattern of this malignant tissue that is diffuse and in consequence, is not completely eliminated by surgical resection. Glioblastomas multiforme are one of the most aggressive forms of brain tumors and after diagnosis, are associated with a poor prognosis and with survival periods of approximately 14 months. In this work, we tested the potentiality of ZnPc and one of its derivatives, TAZnPc, to photoinactivate glioblastoma cells and analyzed the cellular mechanisms involved in the PDT response in vitro.
The penetration of light into living tissues depends on several parameters: intensity, polarization and coherence of the light source, tissue composition and hydration, tissue compression and the light wavelength used to activate the PS. It is known that some PSs that are excited at longer wavelengths have the potential to increase treatment depths in PDT of tumors40. We observed that TAZnPc shows a shift to higher λmax in the absorption spectra as compared to ZnPc. This photochemical property allows the use of light of a longer wavelength, which deeply penetrates the tissue thus favoring the activation of Pc accumulated in cells located deep in the tissue12,16,25,26.
No changes in cell viability were observed with either Pcs when the cells where incubated with concentrations ≤0.5 µM. The cellular uptake of these Pcs (direct and indirectly measured by determining the amount of intracellular Pc and the change in cellular fluorescence, respectively) presents a maximum at 18 hours with non-significant changes at 24 hours (less than 10%). A recent report of Soriano et al.41 shows that ZnPc-DMF is incorporated into human lung adenocarcinoma cells by means of caveolin-mediated endocytosis and that the PS is activated by light41. Our results suggest that both ZnPc and TAZnPc are incorporated into T98G glioblastoma cells in a time dependent fashion. Since it has been proposed that the site of accumulation of the PS is the site of action after activation by light, we evaluated the subcellular accumulation of both phthalocyanines in T98G cells having found that ZnPc accumulates preferentially in mitochondria but also in lysosomes, results similar as those previously reported for other cell lines36,37,42. Interestingly, TAZnPc accumulates predominantly in the lysosomes suggesting that this organelle is the principal site of action of this PS.
Glioblastoma cell photoinactivation was observed in cell cultures treated with ZnPc as well as with TAZnPc. In addition, both ZnPc and TAZnPc show a direct relation between cell photoinactivation and Pc concentration plus light dose delivered. A reduction of ~90% in cell viability was achieved after irradiating cells previously incubated with 0.5 µM of either Pcs, with a higher light dose (27 J/cm2), meanwhile a light dose of 10 J/cm2 trigger a lower reduction in cells treated with TAZnPc as compared with those previously incubated with ZnPc.
It’s known that brain tumors, specially glioblastomas, present a higher recurrence after surgery since the complete elimination is difficult because tumor limits are diffuse and in consequence remaining tumor cells allows the growing of tumors after the initial treatment. In line with this observation, we evaluate the clonogenic capacity of treated cells after PDT and the results obtained indicate that cells treated with ZnPc do not retain proliferation capability after PDT using either light doses. Similar results were found in cells treated with TAZnPc and higher light-dose, however, a clonogenic capacity was observed in lower light dose-treated cells (10 J/cm2). All together, these results can be correlated with the singlet oxygen production observed (ΦΔ), which indicates that TAZnPc has a reduced capacity to produce this high-energy state molecular oxygen specie as compared with ZnPc.
Cell death by the apoptotic pathway constitutes the most desirable outcome of tumor treatment since it represents the physiological cell death mechanism and does not trigger inflammation or immune response. Since PDT using Pcs triggers apoptotic events by damaging critical organelles of the cells43, we studied the mechanism of cell death in T98G cell treated with ZnPc or TAZnPc. The apoptotic pathway involves the early activation of caspase 3, one of the mayor effector caspases44 and a clearly observable nucleus fragmentation. These apoptotic events were evident in cells incubated with ZnPc and irradiated with the either light dose as compared to cells treated with TAZnPc in which the caspase 3 activation together with nucleus fragmentation were evident only after irradiation with the highest light dose used. In line with this result, we observed another hallmark of apoptosis, the DNA internucleosomal fragmentation45, as early as 6 hours after cell treatment with ZnPc, while in cells treated with TAZnPc, the DNA laddering was clearly observed in samples obtained 24 hours after irradiation (Supplementary Data) suggesting differences in the timing of the cell death mechanism46.
Early markers of apoptotic events include the externalization of phosphatidylserine in the cellular membrane. In cells treated with either ZnPc or TAZnPc, we observed a rapid increase in the number of cells positive for Annexin V with the differences observed previously, that is, higher light doses must be delivered to cells incubated with TAZnPc to obtain this effect.
Mitochondria play a key role in activating apoptosis in cells47 and the permeabilization of the mitochondrial outer membrane represents the defining event that irrevocably commits a cell to die48. Previous reports, that examined the subcellular localization of Zinc phthalocyanines, suggest that this PS accumulates predominantly in mitochondria and lysosomes36,38,42,49. Based on the results obtained in this report regarding the subcellular localization of both Pcs and considering the evidence present in the literature that highlight the importance of lysosome disruption for the mitochondrial triggered apoptosis39,50,51,52,53,54, we evaluated the morphology and functionality of mitochondria before and after PDT. Mitochondrial morphology dramatically changes in cells treated with ZnPc or TAZnPc shortly after irradiation, suggesting that the singlet oxygen and/or ROS generated affects on the functionality of this organelle. In addition, a change in the mitochondrial membrane potential was clearly observed in cells treated with either Pcs. Both the change in the mitochondrial membrane potential and the externalization of phosphatidylserine on the external side of the cell membrane support that mitochondria is involved in the cell death triggered by the PDT in T98G cells treated with ZnPc or TAZnPc. Moreover, an early disruption of lysosome integrity was observed as soon as 1 hour after irradiation, suggesting that these phenomena could be related to the mitochondrial-associated cell death as reported previously55. The almost totally accumulation of TAZnPc into lysosomes could partially explain the differences in cell injury after irradiation since only when a higher light dose was delivered the response was similar to that observed in ZnPc treated cells irradiated with lower light dose. The lysosomal injury observed in TAZnPc irradiated with high light dose could be related to the mitochondrial damage reported in these cells after a 27 J/cm2 light dose was delivered. The capacity of both Pcs to photoinactivate glioma cells (T98G, MO59, LN229 and U87-MG) highlights the potentiality of these two compounds for PDT in brain tumors.
Pcs are considered excellent candidates to be used as PSs in PDT treatment of different types of tumors. Regarding brain tumors, several studies using different PSs were reported with promising results56,57, but more studies are necessary to probe the effectiveness of this therapeutic strategy as an adjuvant for the treatment of these tumors. The results presented herein support that both Pcs, ZnPc and TAZnPc, have excellent properties that justify testing them in an animal model of glioblastoma. Furthermore, the shift in the λmax absorption observed for TAZnPc is a promising feature for the activation of the Pc accumulated in deeper portions of the tumor.
Herein we report the effectiveness of two Pcs to inactivate glioblastoma cells in culture. Both ZnPc and its derivative TAZnPc are incorporated into the cells and, in combination with light, are able to trigger cell death mainly by apoptosis. This cell death mechanism involves activation of caspase 3 and loss of mitochondrial morphology and functionality, as well as of lysosomal integrity. Early markers of apoptosis (externalization of phosphatidylserine) and fragmentation of DNA were also observed. The development of novel modified PSs for the treatment of brain tumors will be of help to control this devastating disease and to promote PDT as an adjuvant therapy for their treatment.
Materials and Methods
All starting materials were purchased from Sigma-Aldrich. They were used without further purification. Column chromatography was performed on silica gel (70–270 mesh ASTM). UV spectra and fluorescence spectra were recorded on a Shimadzu UV-1800 Agilent Cary Eclipse Fluorescence Spectrophotometer. Microwave monomode CEM-Discovery reactor was used in the synthesis.
Zn(II)phthalocyanine (ZnPc) was obtained from phthalonitrile in DMF (dimethylformamide) via microware assisted synthesis58 and compare with commercially sample (Aldrich).
Zn(II)tetranitrophthalocyanine (TNZnPc). A mixture of 4-nitrophthalonitrile (346 mg, 2 mmol) and zinc(II) acetate dihydrate (109 mg, 0.55 mmol) in 3 ml of DMF were irradiated in a microwave oven at 100 W and 150 °C for 120 min. Then, the reaction mixture was cooled to room temperature and precipitated with 50 ml of water. The green solid was separated by centrifugation and washed with water. Yield: 86%.
Zn(II)tetraminephthalocyanine (TAZnPc) was synthesized from TNZnPc as previously reported59.
The products characterization UV-visible, fluorescence and 1HNMR are in Supplementary Material.
Quantum yields of singlet oxygen photogeneration were determined using the relative method with unsubstituted zinc phthalocyanine and photooxidation of DMA (9,10-dimethylanthracene)60,61. The kinetics of DMA photooxidation was studied by following the decrease of the absorbance (A) at λmax = 378 nm. The rate constants (kobs) were obtained by a linear least-square fit of the semilogarithmic plot of Ln A0/A vs. time. Solutions of DMA (35 µM) and PS in DMF (sensitizer absorbance 0.2) were irradiated in 1 cm path length quartz cells (2 mL) with monochromatic light at λirr = 670 nm, from a LED NES110NR lamp (Red (625 nm) Lustrous-green Technology of Lightings). ZnPc (ΦΔ = 0.56) was used as a reference in DMF33. All the experiments were performed at 25.0 ± 0.5 °C. The pooled standard deviation of the kinetic data, using different prepared samples, was less than 10%.
TAZnPc fluorescence quantum yield ΦF was calculated by comparison of the area below the corrected emission spectrum with that of ZnPc as standard, λexc = 640 nm, ΦFZnPc: 0,17 (in DMF)32. Spectra were recorded using 1 cm path length quartz cells at 25.0 ± 0.5 °C.
Irradiation was performed using a 150 W/21 V quartz halogen lamp (see spectrum in Supplementary Fig. 3). The light was filtered through a 2.5 cm glass cuvette filled with water to absorb heat at 5 cm of lamp. The sample was at 15.0 cm of lamp. A wavelength range between 350 and 800 nm was selected by optical filters. The light fluence rate at the treatment site was 12.5 mW/cm2 and the light doses of 10 and 27 J/cm2 (See Supplementary Material).
Cell culture conditions
T98G, MO59, LN229 and U87-MG glioma cell lines (ATCC American Type Culture Collection) were cultured in DMEM (Dulbecco’s modified Eagle medium) supplemented with 10% of fetal bovine serum (FBS) and penicillin/streptomycin as antibiotic (Gibco) at 37 °C in a humidified incubator with 5% carbon dioxide atmosphere.
Cell viability determination
Cell viability was determined using alamarBlue Cell viability reagent (Invitrogen) following the protocol provided by the manufacturer. Briefly, cells were incubated with the reagent alamarBlue (10 µL) dissolved in 90 µL of DMEM supplemented with 10% of FBS (final volume: 100 µL in 96 multiwell plate), during 4 hours at 37 °C. Fluorescence measurements were done using a Biotek microplate reader with an excitation wavelength of 540–570 nm and the fluorescence emission reads at 580–610 nm.
Subcellular localization of PSs
T98G were seeded onto coverslips and cultured overnight as described at cell culture conditions. Pc at final concentration of 0.5 μM were added diluted in DMEM supplemented with 4% of FBS and antibiotics, and incubated during 18 hours. Then, the medium was discarded, the cells washed twice using phosphate buffer saline (PBS) 1X and incubated with organelles specific probes: LysoTracker Green (lysosomes) and MitoTracker Green (mitochondria) following the manufacturer instructions (Invitrogen). After incubation, medium with probes was discarded, freshly medium added to cells and then the cells were observed in vivo under confocal microscopy. The sensitizer fluorescence was monitored with an Olympus FV1200 confocal microscope using the following settings: Excitation at 635 nm and emission evaluated at 660–720 nm for ZnPc and 700–730 nm for TAZnPc. The organelle specific probe fluorescence was monitored using the settings recommended by the manufacturer. Image analysis and the Pearson’s correlation coefficient calculated was performed using ImageJ software.
Cellular uptake was determined by two methods, direct measuring of fluorescence62 and flow cytometry63,64. T98G cells were seeded in a 24-well plate (75000 cells/well) and incubated at 37 °C for 24 hours. The different Pcs were added to cells at concentration of 0.5 µM and incubated during 1, 3 and 18 hours in absence of light. Medium was removed, cells washed twice with 500 µL of PBS, counted and lysed using 500 µL of SDS 2% during 1 h. The concentration of Pc in the cell lysate was determined by dilution of 300 µL of cell lysate with 200 µL of DMF and measuring the fluorescence of the samples (ZnPc: λex:640 nm, λem:675 nm, TAZnPc λex:670 nm, λem:711 nm) using an Agilent Cary Eclipse Fluoresence Spectrophotometer. Calibration curves were prepared by dilution of Pc stock solution in DMF at desired concentration in cell lysate (300 µL) diluted in DMF (200 µL). For flow cytometry, cells were trypsinized, centrifuged and resuspended in PBS 1X. Pc fluorescence was determined using the following cytometer settings: excitation at 633 nm and emission acquired using a long pass filter (780 ± 60 nm) in a Becton Dickinson FACSCanto II cytometer.
To evaluate the cytotoxicity of Pc in the absence of irradiation, T98G cells were seeded in 96 well plates (7000 cells/well) and incubated for 24 hours in DMEM supplemented with 10% of FBS plus antibiotics. Then, medium was replaced and the cells were incubated in the presence of different concentration of the PS dissolved in DMEM supplemented with 4% of FBS plus antibiotics. After 18 hours of incubation, medium was discarded and viability was determined using alamarBlue (Invitrogen) as described above.
Cells were seeded in 96 well plates at a density of 7000 cells/well and grown overnight at 37° in DMEM supplemented with 10% of FBS plus antibiotics. Medium was replaced with DMEM supplemented with 4% of FBS containing the photosensitizer at the desired concentration and cells were incubated for 18 hours at 37 °C. Then, the culture medium was replaced with 10% FBS supplemented DMEM medium and cells were irradiated using a homemade device at the desired light dose (10 or 27 J/cm2). Light dose was determined using a SE-9087 Digital Light Meter (Extech Instruments). Viability was examined 24 hours after illumination using alamarBlue (Invitrogen) as described previously and expressed referred to control cells (cells non-irradiated without Pc).
Cells were treated as described above in Photocytotoxicity and 24 hours after, cells were trypsinized, counted, diluted and plated. Plates were returned to the incubator for 8–10 additional days. Then, cell media was removed and cells rinsed using 1X PBS and stained using 500 µL of fixing/staining solution (0.05% crystal violet, 1% formaldehyde, 1% methanol in PBS 1X) during 30 minutes at room temperature and washed using water. After air drying, plates were photographed and counted. Survival fraction was calculated as (number of colonies formed/number of cells seeded × plate efficiency) × 100. Plate efficiency was calculated using control cells and the following formula: PE = (number of colonies formed/number of cells seeded). All experiments were carried out in triplicate and data presented as mean values ± SEM.
Immunodetection of cleaved caspase 3
Cells were seeded on slides in 24 multiwell plates at a density of 150000 cells/well and grown overnight at 37 °C. PDT treatment was performed as described above; then, cells were washed twice with cold PBS 1X and fixed using 4% paraformaldehyde at room temperature for 10 min. Fixed cells were permeabilized in PBS 1X Triton X-100 0.1% during 10 min at room temperature and then washed twice using PBS 1X. Coverslips were blocked with PBS 1X/Bovine Serum Albumin (BSA) 3% during 2 hours at room temperature and incubated overnight at 4 °C with anti-cleaved caspase 3 (1:400, Cell Signaling). After washing, cells were incubated with anti-rabbit Alexa 546 antibody (1:1000, Molecular Probes, USA) for 1 hour at room temperature. Nuclei staining was done during 10 min at room temperature by incubation with 4’,6-diamidino-2-phenylindole (DAPI). Coverslips were mounted with FluorSave (Calbiochem, San Diego, USA) and visualized under an Olympus FV1000 confocal microscope. For the quantification, at least 10 microphotographs of cells submitted to each treatment were analyzed.
Detection of apoptosis and necrosis: Annexin V – PI staining
The determination of cell death mode was performed three hours after PDT. Floating cells were collected and washed with PBS 1X. Attached cells were collected by incubation with trypsin during 2 min. Cell surface exposed phosphatidylserine was evaluated using Annexin-V FITC conjugate (Invitrogen) following the manufacturer´s recommended protocol. Cells were incubated also with PI and then analyzed by flow cytometry. Cells were classified as follow: alive cells (Annexin V−PI−), cells undergoing early apoptosis (Annexin V+ PI−), cells undergoing late apoptosis (Annexin V+ PI+) or cells undergoing necrosis (Annexin V− PI+).
Mitochondrial membrane potential (MMP)
To evaluate the mitochondrial membrane potential after PDT, cells were stained using MitoTracker red CMXRos and Annexin-V FITC conjugated (both from Invitrogen). Three hours after PDT, cells were collected by trypsinization and stained using MitoTracker red CMXRos for 30 min as recommended by the manufacturer. After washing, cells were incubated with Annexin V FITC conjugated and analyzed by flow cytometry. The mitochondrial morphology after PDT was assessed using MitoTracker red CMXRos staining as described above. After staining, cells were fixed, the coverslips were mounted with FluorSave (Calbiochem, San Diego, USA), visualized under an Olympus FV1000 confocal microscope and the images were acquired with the XYZ resolution needed for restoration by deconvolution. The stack of images was deconvolved using Huygens Deconvolution software (SVI, Netherlands).
Lysosome disruption after PDT. LysoTracker Green retention assay
In order to evaluate the integrity of lysosomes after PDT we analyzed the capacity of the cells to retain the organelle specific probe LysoTracker Green after PDT following the protocol described previously65. Briefly, cells were incubated with LysoTracker Green at concentration of 25 nM dissolved in DMEM supplemented with 10% FBS and antibiotics during 30 minutes. After this, medium was discarded and new fresly medium was added to ceels prior irradiation. One hour after irradiation cells were collected and analyzed by flow cytometry. Mean fluorescence intensity was obtained and compared to cells without irradiation.
DNA fragmentation analysis
DNA fragmentation analysis was performed as described previously66. Briefly, after PDT treatment (6 or 24 hours), adherent and non-adherent cells were collected by centrifugation at 1200 rpm during 5 min and washed using cold PBS 1X. Then, cells were lysed in ice-cold lysis buffer (0.15 M NaCl, 10 mM Tris-HCl pH 7.8, 2 mM MgCl2, 1 mM DTT and 0.5% NP-40) during 40 min on ice. Lysates were centrifuged at 1500 rpm during 10 min, pellets were resuspended in ice-cold buffer containing 0.35 M NaCl, 10 mM Tris-HCl, 1 mM MgCl2 and 1 mM DTT and incubated on ice for 20 min. Then, DNA was extracted with phenol-chloroform and precipitated with 0.01 M MgCl2 and 2.5 volumes of 100% ethanol overnight at −20 °C. DNA was collected by centrifugation at 14000 rpm for 20 min, resuspended in 10 mM Tris-1 mM EDTA with 0.1 mg/mL RNase A, and incubated at 37 °C for 1 hour. Finally, DNA electrophoresis was performed in 1.5% agarose gel containing ethidium bromide and visualized under UV light.
Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N Engl J Med 359, 492–507 (2008).
Wilson, T. A., Karajannis, M. A. & Harter, D. H. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 5, 64 (2014).
Laquintana, V. et al. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6, 1017–1032 (2009).
van Tellingen, O. et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 19, 1–12 (2015).
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987–996 (2005).
Cheng, L., Bao, S. & Rich, J. N. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 80, 654–665 (2010).
Yang, C., Jin, K., Tong, Y. & Cho, W. C. Therapeutic potential of cancer stem cells. Med Oncol 32, 619 (2015).
Campos, B., Olsen, L. R., Urup, T. & Poulsen, H. S. A comprehensive profile of recurrent glioblastoma. Oncogene 35, 5819–5825 (2016).
Wan, M. T. & Lin, J. Y. Current evidence and applications of photodynamic therapy in dermatology. Clin. Cosmet. Investig. Dermatol. 7, 145–63 (2014).
Dolmans, D. E., Fukumura, D. & Jain, R. K. Photodynamic therapy for cancer. Nat Rev Cancer 3, 380–387 (2003).
Ost, D. Photodynamic therapy in lung cancer. A review. Methods Mol Med 75, 507–526 (2003).
Yoon, I., Li, J. Z. & Shim, Y. K. Advance in photosensitizers and light delivery for photodynamic therapy. Clin Endosc 46, 7–23 (2013).
Acedo, P., Stockert, J. C., Canete, M. & Villanueva, A. Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer. Cell Death Dis 5, e1122 (2014).
Robertson, C. A., Evans, D. H. & Abrahamse, H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B 96, 1–8 (2009).
Allison, R. R. & Moghissi, K. Photodynamic Therapy (PDT): PDT Mechanisms. Clin Endosc 46, 24–29 (2013).
Allison, R. R. & Sibata, C. H. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn Ther 7, 61–75 (2010).
Buytaert, E., Dewaele, M. & Agostinis, P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776, 86–107 (2007).
Castano, A. P., Demidova, T. N. & Hamblin, M. R. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther 2, 1–23 (2005).
Perria, C. et al. Fast attempts at the photodynamic treatment of human gliomas. J Neurosurg Sci 24, 119–129 (1980).
Stylli, S. S., Kaye, A. H., MacGregor, L., Howes, M. & Rajendra, P. Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci 12, 389–398 (2005).
Muller, B. C. & Photodynamic, P. W. therapy of brain tumor—a work in progress. Laser Surg Med 38, 384–389 (2006).
Kostron, H. & Rossler, K. [Surgical intervention in patients with malignant glioma]. Wien Med Wochenschr 156, 338–341 (2006).
Akimoto, J., Haraoka, J. & Aizawa, K. Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas. Photodiagnosis Photodyn Ther 9, 91–99 (2012).
Muragaki, Y. et al. Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg 119, 845–852 (2013).
Wilson, B. C., Jeeves, W. P. & Lowe, D. M. In vivo and post mortem measurements of the attenuation spectra of light in mammalian tissues. Photochem Photobiol 42, 153–162 (1985).
Szacilowski, K., Macyk, W., Drzewiecka-Matuszek, A., Brindell, M. & Stochel, G. Bioinorganic Photochemistry: Frontiers and Mechanisms. Chem. Rev. 105 (2005).
Bonnet, R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem. Soc. Rev. 24, 19–23 (1995).
Chin, Y. et al. Improved photodynamic efficacy of Zn(II) phthalocyanines via glycerol substitution. PLoS One 9, e97894 (2014).
A, M. G. et al. Photodynamic performance of zinc phthalocyanine in HeLa cells: A comparison between DPCC liposomes and BSA as delivery systems. J Photochem Photobiol B 163, 385–390 (2016).
Xu, D. et al. In vitro photodynamic therapy on human U251 glioma cells with a novel photosensitiser ZnPcS4-BSA. Br J Neurosurg 24, 660–665 (2010).
Zorlu, Y., Dumoulin, F., Durmuş, M. & Ahsen, V. Comparative studies of photophysical and photochemical properties of solketal substituted platinum(II) and zinc(II) phthalocyanine sets. Tetrahedron 66, 3248–3258 (2010).
Ogunsipe, A., Maree, D. & Nyokong, T. Solvent effects on the photochemical and fluorescence properties of zinc phthalocyanine derivatives. J. Mol. Struct. 650, 131–140 (2003).
Spiller, W. et al. Singlet Oxygen Quantum Yields of Different Photosensitizers in Polar Solvents and Micellar Solutions. J. Porphyr. Phthalocyanines 2, 145–158 (1998).
Nonell, S. & Flors, C. Singlet Oxygen: Applications in Biosciences and Nanosciences. 1, (Royal Society of Chemistry, 2016).
Chiu, S. M. et al. A requirement for bid for induction of apoptosis by photodynamic therapy with a lysosome- but not a mitochondrion-targeted photosensitizer. Photochem Photobiol 86, 1161–1173 (2010).
Alexandratou, E., Yova, D. & Loukas, S. A confocal microscopy study of the very early cellular response to oxidative stress induced by zinc phthalocyanine sensitization. Free Radic Biol Med 39, 1119–1127 (2005).
Fabris, C. et al. Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis. Cancer Res 61, 7495–7500 (2001).
Shao, J. et al. Intracellular distribution and mechanisms of actions of photosensitizer Zinc(II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. Cancer Lett 330, 49–56 (2013).
Tsubone, T. M. et al. Enhanced efficiency of cell death by lysosome-specific photodamage. Sci. Rep. 7, 6734 (2017).
Lee, L. K., Whitehurst, C., Pantelides, M. L. & Moore, J. V. In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Photochem Photobiol 62, 882–886 (1995).
Soriano, J., Villanueva, A., Stockert, J. C. & Cañete, M. Vehiculization determines the endocytic internalization mechanism of Zn(II)-phthalocyanine. Histochem Cell Biol 139, 149–160 (2013).
Vittar, N. B., Prucca, C. G., Strassert, C., Awruch, J. & Rivarola, V. A. Cellular inactivation and antitumor efficacy of a new zinc phthalocyanine with potential use in photodynamic therapy. Int J Biochem Cell Biol 40, 2192–2205 (2008).
Mfouo-Tynga, I. & Abrahamse, H. Cell death pathways and phthalocyanine as an efficient agent for photodynamic cancer therapy. Int J Mol Sci 16, 10228–10241 (2015).
Taylor, R. C., Cullen, S. P. & Martin, S. J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9, 231–241 (2008).
Elmore, S. Apoptosis: a review of programmed cell death. Toxicol Pathol 35, 495–516 (2007).
Agarwal, M. L. et al. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res. 51, 5993–6 (1991).
Wang, C. & Youle, R. J. The role of mitochondria in apoptosis*. Annu Rev Genet 43, 95–118 (2009).
Lopez, J. & Tait, S. W. Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer 112, 957–962 (2015).
Pavani, C., Uchoa, A. F., Oliveira, C. S., Iamamoto, Y. & Baptista, M. S. Effect of zinc insertion and hydrophobicity on the membrane interactions and PDT activity of porphyrin photosensitizers. Photochem. Photobiol. Sci. 8, 233–240 (2009).
Kessel, D. & Reiners, J. J. Enhanced efficacy of photodynamic therapy via a sequential targeting protocol. Photochem. Photobiol. 90, 889–95 (2014).
Kessel, D. Subcellular targets for photodynamic therapy: implications for initiation of apoptosis and autophagy. J. Natl. Compr. Canc. Netw. 10(Suppl 2), S56–9 (2012).
Rodriguez, M. E. et al. Structural factors and mechanisms underlying the improved photodynamic cell killing with silicon phthalocyanine photosensitizers directed to lysosomes versus mitochondria. Photochem. Photobiol. 85, 1189–200 (2009).
Tynga, I. M., Houreld, N. N. & Abrahamse, H. The primary subcellular localization of Zinc phthalocyanine and its cellular impact on viability, proliferation and structure of breast cancer cells (MCF-7). J. Photochem. Photobiol. B. 120, 171–6 (2013).
Kessel, D. Apoptosis and associated phenomena as a determinants of the efficacy of photodynamic therapy. Photochem. Photobiol. Sci. 14, 1397–402 (2015).
Kessel, D. & Evans, C. L. Promotion of Proapoptotic Signals by Lysosomal Photodamage: Mechanistic Aspects and Influence of Autophagy. Photochem. Photobiol. 92, 620–3 (2016).
Vanaclocha, V. et al. Photodynamic therapy in the treatment of brain tumours. A feasibility study. Photodiagnosis Photodyn Ther 12, 422–427 (2015).
Quirk, B. J. et al. Photodynamic therapy (PDT) for malignant brain tumors–where do we stand? Photodiagnosis Photodyn Ther 12, 530–544 (2015).
Gerdes, R., Lapok, L., Tsaryova, O., Wohrle, D. & Gorun, S. M. Rational design of a reactive yet stable organic-based photocatalyst. Dalt. Trans 1098–1100, https://doi.org/10.1039/b822111c (2009).
Cong, F. D. et al. Facile synthesis, characterization and property comparisons of tetraaminometallophthylocyanines with and without intramolecular hydrogen bonds. Dye. Pigment. 66, 149–154 (2005).
Gomes, A., Fernandes, E. & Lima, J. L. Fluorescence probes used for detection of reactive oxygen species. J. Biochem. Methods 65, 45–80 (2005).
Maree, S. E. & Nyokong, T. Syntheses and photochemical properties of octasubstituted phthalocyaninato zinc complexes. J. Porphyrins Phthalocyanines 05, 782–792 (2001).
Hofman, J. W. et al. Peripheral and axial substitution of phthalocyanines with solketal groups: synthesis and in vitro evaluation for photodynamic therapy. J Med Chem 50, 1485–1494 (2007).
Schimanski, A. et al. Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment. J Photochem Photobiol B 163, 203–210 (2016).
Postigo, F., Sagrista, M. L., De Madariaga, M. A., Nonell, S. & Mora, M. Photosensitization of skin fibroblasts and HeLa cells by three chlorin derivatives: Role of chemical structure and delivery vehicle. Biochim Biophys Acta 1758, 583–596 (2006).
Hornick, J. R. et al. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J. Exp. Clin. Cancer Res. 31, 41 (2012).
Gooch, J. L. & Yee, D. Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett 144, 31–37 (1999).
We would like to thank NBRV for helpful discussions. Excellent technical assistance from Carlos R. Mas, Cecilia Sampedro, Pilar Crespo and Paula Abadie is also acknowledged. F.N.V and M.M. are fellows and M.T.B, B.L.C., T.C.T, and C.G.P are career members of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET- Argentina). The work was supported by grants from the Agencia Nacional de Promocion Cientifica y Tecnologica, Secretaría de Ciencia, Tecnología e Innovación Productiva de Argentina, Instituto Nacional del Cancer, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Secretaría de Ciencia y Tecnología, Universidad Nacional de Córdoba (SeCyT), Ministerio de Ciencia y Tecnología de la Provincia de Córdoba.
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Velazquez, F.N., Miretti, M., Baumgartner, M.T. et al. Effectiveness of ZnPc and of an amine derivative to inactivate Glioblastoma cells by Photodynamic Therapy: an in vitro comparative study. Sci Rep 9, 3010 (2019). https://doi.org/10.1038/s41598-019-39390-0